Could a diabetes drug ease heart failure in rare amyloid disease?
NCT ID NCT05795400
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug dapagliflozin (a diabetes medicine) in 50 adults with heart failure due to amyloid cardiomyopathy, a rare condition where abnormal proteins stiffen the heart. Researchers measured changes in quality of life, walking distance, and heart stress markers over time. The goal was to see if the drug can safely ease symptoms and improve daily function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
50 people
The number who actually took part.
- Started
-
Jun 2022
- Finished
-
Sep 2025
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Males and females between 18 and 80 years of age 2. HF, confirmed with the increased level of NT-proBNP\>300 pg/mL or BNP\>100 pg/mL 3. Transthyretin amyloid cardiomyopathy, confirmed with echocardiography and/or contrast-enhanced cardiac MRI Exclusion Criteria: 1. The inability to continue all the activities planned in this study by the patient. 2. The onset of pregnancy. 3. Patient's voluntary withdrawal of consent to participate in a clinical trial at any point during the conduct of the study. 4. Development of intolerable side effects. 5. Administration of disease-modifying treatment of amyloidosis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amyloid cardiomyopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Moscow, 121552, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can biomarkers predict which elderly heart failure patients will return to hospital?
- Can a daily pill shield hearts in HFpEF?
- Could a handheld ultrasound help clinics spot heart failure sooner?
- Can yoga classes rival standard rehab for a failing heart?
- Implanted device aims to ease heart failure symptoms
- Heart failure drug probed for hidden benefit on lung pressure